CompletedPhase 2NCT02961374
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Studying Attenuated familial adenomatous polyposis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Niloy J SamadderMayo Clinic
- Intervention
- Erlotinib(drug)
- Enrollment
- 46 enrolled
- Eligibility
- 18-69 years · All sexes
- Timeline
- 2017 – 2021
Study locations (8)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
- University of Puerto Rico, San Juan, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02961374 on ClinicalTrials.gov